HB
NTLA icon

Homrich & Berg’s Intellia Therapeutics NTLA Stock Holding History

Homrich & Berg’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$268K Hold
2,000
– – 0.01% 379
2021
Q2 		$324K Buy
+2,000
New +$156K 0.01% 352

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Homrich & Berg's NTLA Position: Q3 2021 in Review

Homrich & Berg held its Intellia Therapeutics (NTLA) position steady in Q3 2021 at 2,000 shares worth $268K. The position accounts for 0.01% of the portfolio, ranked #379.

Homrich & Berg first reported a position in NTLA in Q2 2021 and has held it in 2 quarters since. The position peaked at $324K in Q2 2021. 365 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Homrich & Berg held 2,000 shares of Intellia Therapeutics worth $268K as of Q3 2021.
  • Homrich & Berg left its Intellia Therapeutics share count unchanged in Q3 2021.
  • Intellia Therapeutics made up 0.01% of Homrich & Berg's portfolio in Q3 2021, its #379 holding.
  • Homrich & Berg first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Homrich & Berg's Intellia Therapeutics position peaked at $324K in Q2 2021.
  • 365 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Homrich & Berg's 13F filing for Q3 2021, filed 8 Dec 2021.